Article Text

Download PDFPDF
Randomised controlled trial
The administration of corticosteroids to 34–36-week pregnant women at risk of imminent delivery does not reduce the risk of respiratory disorders in the newborn
  1. Kellie Estelle Murphy
  1. Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Kellie Estelle Murphy
    Department of Obstetrics and Gynecology, University of Toronto, 700 University Avenue, Room 3278, Toronto, ON M5G 1Z5, Canada; kmurphy{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


A single course of antenatal corticosteroids (ACS) is an unusual example of an intervention which leads to a cost savings and an improved health outcome for infants born before 34-week gestational age (GA).1 However, the evidence with regards to its effectiveness in late preterm infants (those born between 34 and before 36 6/7 weeks) is unknown.


A single-centre, double-blind, randomised controlled trial of a single course of antenatal corticosteroids versus placebo in women at high risk of preterm birth between 34 and 36 6/7 weeks GA. Between April 2008 and June 2010, 320 women were randomised, 163 to ACS and 157 to placebo, at a large tertiary hospital in Recife, Brazil. Women randomised to …

View Full Text


  • Competing interests None.